treatment-resistant depression – Discover Pharma

Welcome to Discover Pharma! Today is : May 27, 2026

treatment-resistant depression

Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression
Alto Neuroscience has started a Phase 2b trial of ALTO-207 [...]

May 5, 2026
Central Nervous System,Drug Discovery & Development,Therapeutic Areas
Strategies to extend ketamine antidepressant effects identified in new study
Researchers have identified a molecular target that could extend the [...]

May 5, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
Compass Pathways reports positive second Phase 3 trial for COMP360 in treatment-resistant depression
Compass Pathways has reported that its second pivotal Phase 3 [...]

May 5, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference
FundaMental Pharma GmbH will present new preclinical data on its [...]

May 5, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
Alto Neuroscience secures new US method-of-treatment patent for ALTO-207 in depression
Alto Neuroscience has strengthened its intellectual property position around its [...]

May 5, 2026
Drug Discovery & Development
Elkedonia raises EUR 11.25 million to develop new treatment for depression and other neuropsychiatric disorders
New approach targets Elk1 to restore neuroplasticity without sedation or [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK